Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single
administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal
dialysis.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.